Mark L. Fischer

Array ( [id] => 18581629 [patent_doc_number] => 20230263882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST CORONAVIRUS [patent_app_type] => utility [patent_app_number] => 18/012343 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552483 [patent_doc_number] => 20230250493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => KIT AND METHODS FOR CHARACTERIZING A VIRUS IN A SAMPLE [patent_app_type] => utility [patent_app_number] => 18/012879 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480680 [patent_doc_number] => 20220088184 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE [patent_app_type] => utility [patent_app_number] => 17/350008 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18716549 [patent_doc_number] => 11793872 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Modified MRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/349929 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 34 [patent_no_of_words] => 30585 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17349929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17290965 [patent_doc_number] => 20210386804 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients [patent_app_type] => utility [patent_app_number] => 17/343851 [patent_app_country] => US [patent_app_date] => 2021-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17343851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17256853 [patent_doc_number] => 20210369838 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => METHODS OF USING HSV-2 SINGLE CYCLE VIRUS DELTA-GD AND HSV-2 RECOMBINANT GLYCOPROTEIN D [patent_app_type] => utility [patent_app_number] => 17/335548 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17335548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214795 [patent_doc_number] => 20210348132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => SCALABLE PURIFICATION METHOD FOR AAV1 [patent_app_type] => utility [patent_app_number] => 17/328687 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533693 [patent_doc_number] => 20220112302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/328895 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545494 [patent_doc_number] => 11718835 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Scalable purification method for AAV8 [patent_app_type] => utility [patent_app_number] => 17/328686 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13575 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449641 [patent_doc_number] => 20230190917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => VIRAL VACCINE VECTOR FOR IMMUNIZATION AGAINST A BETACORONAVIRUS [patent_app_type] => utility [patent_app_number] => 17/925988 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227187 [patent_doc_number] => 20210353743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => BIOMATERIAL-BASED COVID-19 VACCINE [patent_app_type] => utility [patent_app_number] => 17/322054 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17322054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18693010 [patent_doc_number] => 20230323389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES [patent_app_type] => utility [patent_app_number] => 17/999170 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36531 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497385 [patent_doc_number] => 20230220012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => HIGH-POTENCY SARS CORONAVIRUS 2 ANTIGEN AND VACCINE COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/998729 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18404601 [patent_doc_number] => 20230165952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-01 [patent_title] => BETACORONAVIRUS PROPHYLAXIS AND THERAPY [patent_app_type] => utility [patent_app_number] => 17/997407 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091379 [patent_doc_number] => 20220409720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => VARICELLA ZOSTER VIRUS (VZV) VACCINE [patent_app_type] => utility [patent_app_number] => 17/245973 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17201385 [patent_doc_number] => 20210341480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => VIRAL TESTING IN SALIVA [patent_app_type] => utility [patent_app_number] => 17/244333 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4550 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418603 [patent_doc_number] => 20230173061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => HUMAN CYTOMEGALOVIRUS POLYEPITOPE VACCINE COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/921945 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17921945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18526461 [patent_doc_number] => 11713449 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-01 [patent_title] => Scalable purification method for AAVRH10 [patent_app_type] => utility [patent_app_number] => 17/236448 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 20 [patent_no_of_words] => 17261 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17236448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170816 [patent_doc_number] => 20210324486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => Method and Primers for the Sensitive and Specific Detection of SARS-CoV-2 [patent_app_type] => utility [patent_app_number] => 17/235348 [patent_app_country] => US [patent_app_date] => 2021-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17235348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17005470 [patent_doc_number] => 20210236631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANT [patent_app_type] => utility [patent_app_number] => 17/231534 [patent_app_country] => US [patent_app_date] => 2021-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17231534 [rel_patent_id] =>[rel_patent_doc_number] =>)